Revance Therapeutics, Inc.
RVNC · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Revenue | $234 | $133 | $78 | $15 |
| % Growth | 76.5% | 70.4% | 407.7% | – |
| Cost of Goods Sold | $152 | $52 | $23 | $5 |
| Gross Profit | $82 | $81 | $54 | $11 |
| % Margin | 35% | 61% | 69.9% | 68.9% |
| R&D Expenses | $79 | $101 | $116 | $126 |
| G&A Expenses | $39 | $37 | $193 | $150 |
| SG&A Expenses | $292 | $220 | $199 | $152 |
| Sales & Mktg Exp. | $253 | $183 | $6 | $2 |
| Other Operating Expenses | $27 | $28 | $14 | $6 |
| Operating Expenses | $399 | $353 | $329 | $284 |
| Operating Income | -$317 | -$272 | -$275 | -$273 |
| % Margin | -135.4% | -205.3% | -353.1% | -1,782.5% |
| Other Income/Exp. Net | -$7 | -$14 | -$7 | -$12 |
| Pre-Tax Income | -$324 | -$356 | -$281 | -$285 |
| Tax Expense | $0 | $1 | $0 | -$3 |
| Net Income | -$324 | -$356 | -$287 | -$282 |
| % Margin | -138.4% | -268.9% | -368.7% | -1,840.7% |
| EPS | -3.83 | -4.9 | -4.25 | -4.86 |
| % Growth | 21.8% | -15.3% | 12.6% | – |
| EPS Diluted | -3.83 | -4.9 | -4.25 | -4.86 |
| Weighted Avg Shares Out | 85 | 73 | 68 | 58 |
| Weighted Avg Shares Out Dil | 85 | 73 | 68 | 58 |
| Supplemental Information | – | – | – | – |
| Interest Income | $13 | $5 | $0 | $4 |
| Interest Expense | $19 | $16 | $6 | $15 |
| Depreciation & Amortization | $14 | $34 | $20 | $10 |
| EBITDA | -$291 | -$306 | -$255 | -$259 |
| % Margin | -124.2% | -230.5% | -328% | -1,692.1% |